What is Partillion Bioscience?
Partillion Bioscience is at the forefront of functional single-cell biology, developing the world's first reagent platform that leverages nanovial technology for precise single-cell secretion analysis. Their comprehensive product suite includes specialized antibody discovery kits, developer kits, and custom orders, all designed to empower researchers in cell therapies and immunology. The company's technology is particularly valuable for scientists engaged in clinical trials and cell therapy development, offering tools for high-throughput screening and in-depth analysis of cellular functions. Partillion's commitment to making advanced single-cell research more accessible and affordable is driving innovation in the field.
How much funding has Partillion Bioscience raised?
Partillion Bioscience has raised a total of $5M across 1 funding round:
Angel/Seed
$5M
Angel/Seed (2023): $5M with participation from Paladin Capital Group, Vertical Venture Partners, and ND Capital
Key Investors in Partillion Bioscience
Paladin Capital Group
Paladin Capital Group is a global multi-stage investment firm specializing in venture capital and growth financing. They strategically deploy capital to support companies from early-stage ventures through expansion phases, leveraging deep sector expertise and operational acumen to accelerate growth.
Vertical Venture Partners
Vertical Venture Partners is an early-stage venture capital firm focused on enterprise technology companies targeting specific vertical markets. They partner with founders who possess deep industry understanding to support business growth and efficiency.
ND Capital
ND Capital GmbH operates in the Finance industry, headquartered in Switzerland. While specific investment focus is not detailed, their participation suggests an interest in innovative ventures.
What's next for Partillion Bioscience?
With a major enterprise-level funding context and a recent strategic investment, Partillion Bioscience is well-positioned for significant scaling and further development of its proprietary nanovial technology. This capital infusion is expected to accelerate the expansion of their product offerings, enhance research and development efforts in cell therapies and immunology, and broaden their market reach. The company's focus on enabling high-throughput single-cell analysis suggests a strategic push towards becoming a key player in the rapidly growing biotech research tools market. Future growth will likely involve strengthening partnerships with research institutions and pharmaceutical companies, further solidifying their role in advancing cellular research.
See full Partillion Bioscience company page
